4.7 Review

Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape

Journal

JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 15, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13045-022-01292-6

Keywords

Hypoxia; Hypoxia-inducible factors; Tumor disease; Immunotherapy; Personalized medicine

Funding

  1. National Natural Science Foundation of China [31972741, 32172922]
  2. Excellent Project PrF UHK [2217/2022-2023]
  3. Czech Republic, Postdoctoral Science Foundation of Jiangsu Province [2016T90477]
  4. European Research Council (ERC) under the European Union [759585]
  5. European Research Council (ERC) [759585] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Hypoxia in the tumor microenvironment weakens cytotoxic T cell function and promotes recruitment of regulatory T cells, thereby reducing tumor immunogenicity. Hypoxia-inducible factors (HIFs), especially HIF1A and HIF2A, play important roles in tumor immune escape through various mechanisms. Understanding these mechanisms can lead to the development of targeted therapies for tumor treatment.
Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Studies have demonstrated that hypoxia and hypoxia-inducible factors (HIFs) 1 and 2 alpha (HIF1A and HIF2A) are involved in tumor immune escape. Under hypoxia, activation of HIF1A induces a series of signaling events, including through programmed death receptor-1/programmed death ligand-1. Moreover, hypoxia triggers shedding of complex class I chain-associated molecules through nitric oxide signaling impairment to disrupt immune surveillance by natural killer cells. The HIF-1-galactose-3-O-sulfotransferase 1-sulfatide axis enhances tumor immune escape via increased tumor cell-platelet binding. HIF2A upregulates stem cell factor expression to recruit tumor-infiltrating mast cells and increase levels of cytokines interleukin-10 and transforming growth factor-beta, resulting in an immunosuppressive tumor microenvironment. Additionally, HIF1A upregulates expression of tumor-associated long noncoding RNAs and suppresses immune cell function, enabling tumor immune escape. Overall, elucidating the underlying mechanisms by which HIFs promote evasion of tumor immune surveillance will allow for targeting HIF in tumor treatment. This review discusses the current knowledge of how hypoxia and HIFs facilitate tumor immune escape, with evidence to date implicating HIF1A as a molecular target in such immune escape. This review provides further insight into the mechanism of tumor immune escape, and strategies for tumor immunotherapy are suggested.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available